Dry Age-related Macular Degeneration Clinical Trial
Official title:
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry age related macular degeneration.
PRIMA is a new photovoltaic sub-retinal wireless prosthesis for partial restoration of visual perception in patients with vision loss from atrophic dry Age-related Macular Degeneration. The implantable part of the device is placed under the retina. A mini camera mounted on a pair of glasses captures the visual scene in the environment. The visual scene is processed and simplified by the pocket computer connected to the glasses in order to extract useful information from the images. The simplified images are then sent back to the glasses where a miniaturized projector then projects the processed images wirelessly via pulses of near infrared light on the PRIMA implant at the back of the eye under the retina. The photovoltaic cells convert this optical information into electrical stimulation to excite the nerve cells of the retina and induce visual perception. In this early feasibility study five human subjects suffering from atrophic dry age related macular degeneration will receive the implant. The performance and the safety of the device will be monitored for up to 36 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03046407 -
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04566445 -
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
|
Phase 2 | |
| Recruiting |
NCT04339764 -
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05536752 -
QA102 Phase II Study in Subjects With Dry AMD
|
Phase 2 | |
| Recruiting |
NCT06351605 -
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)
|
||
| Active, not recruiting |
NCT04065490 -
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
|
N/A | |
| Recruiting |
NCT06229665 -
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
|
Phase 2/Phase 3 | |
| Completed |
NCT01002950 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
|
Phase 2 | |
| Active, not recruiting |
NCT03333954 -
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
|
N/A | |
| Completed |
NCT05667688 -
Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85
|
Phase 1 | |
| Completed |
NCT01379560 -
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT03144999 -
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
|
Phase 1 | |
| Withdrawn |
NCT04511936 -
Microcurrent Stimulation for Dry Age-related Macular Degeneration
|
N/A | |
| Withdrawn |
NCT04358471 -
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
|
Phase 2 | |
| Terminated |
NCT04643886 -
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
|
Phase 2 | |
| Not yet recruiting |
NCT05418231 -
Observation of the Natural Course of Age-related Macular Degeneration
|
||
| Recruiting |
NCT00926861 -
Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD
|
N/A | |
| Active, not recruiting |
NCT04437368 -
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
|
Phase 2 | |
| Active, not recruiting |
NCT03894020 -
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
|
||
| Not yet recruiting |
NCT04875234 -
Vision Improvement for Legally Blind Dry AMD Patients
|